within Pharmacolibrary.Drugs.ATC.S;

model S01ED52
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 6.999999999999999e-06,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01ED52</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Betaxolol is a selective beta-1 adrenergic receptor blocker used primarily for the treatment of elevated intraocular pressure in conditions such as glaucoma and ocular hypertension. As part of combinations classified under ATC S01ED52, it is used topically in ophthalmology, usually in formulations combined with other agents. Betaxolol is approved for clinical use, particularly in the form of eye drops.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not directly reported in literature for betaxolol combinations used in ophthalmic formulations (ATC S01ED52). Parameters below are estimated based on typical topical ophthalmic beta blocker properties and pharmacokinetics reported for single-agent betaxolol in adults.</p><h4>References</h4><ol><li><p>Fayyaz, A, Vellonen, KS, Ranta, VP, Toropainen, E, Reinisalo, M, Valtari, A, Puranen, J, Ricci, GD, Heikkinen, EM, Gardner, I, Ruponen, M, Urtti, A, Jamei, M, &amp; Del Amo, EM (2021). Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: Tissue exposures in the rabbit eye. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 166 155–162. DOI:<a href=\"https://doi.org/10.1016/j.ejpb.2021.06.003\">10.1016/j.ejpb.2021.06.003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34139290/\">https://pubmed.ncbi.nlm.nih.gov/34139290</a></p></li><li><p>Vainio-Jylhä, E, Vuori, ML, Kaila, T, &amp; Huupponen, R (1998). Aqueous humour concentration and the intraocular pressure-lowering effect of topical betaxolol before cataract surgery. <i>European journal of clinical pharmacology</i> 54(5) 389–392. DOI:<a href=\"https://doi.org/10.1007/s002280050480\">10.1007/s002280050480</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9754981/\">https://pubmed.ncbi.nlm.nih.gov/9754981</a></p></li><li><p>Adkins, JC, &amp; Balfour, JA (1998). Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. <i>Drugs &amp; aging</i> 12(3) 225–241. DOI:<a href=\"https://doi.org/10.2165/00002512-199812030-00005\">10.2165/00002512-199812030-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9534022/\">https://pubmed.ncbi.nlm.nih.gov/9534022</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01ED52;
